SeaStar Medical’s director John Neuman acquires $153,227 in shares

SeaStar Medical (TASE:BLWV) Holding Corp (NASDAQ:ICU), a micro-cap healthcare company with a market value of $7.03 million, has seen significant stock activity by its director, John Neuman, according to a recent SEC filing. The company’s shares have declined over 91% in the past year, trading near their 52-week low of $1.50. Neuman purchased a total of 40,000 shares of the company in four separate transactions, amounting to a cumulative value of $153,227.

The transactions occurred over several months, with purchases made on June 14, June 17, August 15, and December 11, 2024. The shares were acquired at prices ranging from $2.0405 to $5.2396 per share. Following these transactions, Neuman now holds 40,000 shares directly.

These acquisitions were reported late due to an administrative error, as noted in the filing. The company’s overall financial health score is currently rated as WEAK by InvestingPro analysts.

In other recent news, SeaStar Medical Holding Corp has been actively navigating several significant developments. The company recently received a public reprimand from Nasdaq due to non-compliance with Listing Rule 5635(d), related to the issuance of shares beyond the approved amount without shareholder consent. Despite this, SeaStar Medical’s stock remains listed on the Nasdaq, as the company has taken corrective measures, including repurchasing outstanding warrants. Meanwhile, SeaStar Medical has secured approximately $6 million through a direct offering with an institutional investor. This transaction, expected to close soon, involves the sale of over 3.5 million shares and pre-funded warrants, with H.C. Wainwright & Co. acting as the exclusive financial advisor.

Additionally, SeaStar Medical faces potential delisting from Nasdaq for failing to meet the minimum market value requirement, which has been below the $35 million threshold for an extended period. The company plans to appeal this decision, which temporarily stays the delisting process, allowing its securities to continue trading on Nasdaq. Investors are closely monitoring SeaStar Medical’s efforts to regain compliance with Nasdaq’s financial standards. These recent developments highlight the company’s ongoing challenges and strategic maneuvers to maintain its position on the stock exchange.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.